Oncocyte Corporation (OCX) earnings
OCX earnings moved a median of +2.12% by the close. Quarterly and annual OCX reports and results, each read against the price at its own news timestamp. Back to the OCX overview →
18 measured OCX earnings events.
Where these OCX earnings landedvs 18 measured OCX earnings reactions
| Middle 50% of OCX earnings reactions | -1.77% to +7.09% |
|---|---|
| Median reaction (to close) | +2.12% |
| Measured reactions | 18 |
Point-in-time · zero look-ahead
Half of the 18 OCX earnings events with a measured close landed between -1.77% and +7.09%; 56% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Oncocyte Corp For: Mar 31 | SEC filing · Form 10-Q | -0.35% | -1.77% | |
| Oncocyte Reports Q1 2025 Results and Business Progress | Press release | -0.35% | -1.77% | |
| Oncocyte to Release First Quarter 2025 Results on May 12, 2025 | Press release | -0.36% | +1.43% | |
| Form 10-K Oncocyte Corp For: Dec 31 | SEC filing · Form 10-K | -6.04% | -16.48% | |
| Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 | Press release | +0.00% | -1.96% | |
| Form 10-Q Oncocyte Corp For: Sep 30 | SEC filing · Form 10-Q | -1.67% | -2.00% | |
| Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 | Press release | — | +0.00% | |
| Form 10-Q Oncocyte Corp For: Jun 30 | SEC filing · Form 10-Q | — | +4.35% | |
| Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results | Press release | — | +4.35% | |
| Oncocyte to Announce Second Quarter 2024 Financial Results on August 8 | Press release | — | -3.91% | |
| Form 10-Q Oncocyte Corp For: Mar 31 | SEC filing · Form 10-Q | +2.22% | +13.70% | |
| Oncocyte Reports First Quarter 2024 Financial Results | Press release | +2.22% | +13.70% | |
| Oncocyte to Announce First Quarter 2024 Financial Results | Press release | — | -0.52% | |
| Form 10-K Oncocyte Corp For: Dec 31 | SEC filing · Form 10-K | -0.13% | +7.42% | |
| Form NT 10-K Oncocyte Corp For: Dec 31 | SEC filing · Form NT | — | +2.81% | |
| Form 10-Q Oncocyte Corp For: Sep 30 | SEC filing · Form 10-Q | +1.15% | +6.11% | |
| Oncocyte Reports Third Quarter 2023 Financial Results | Press release | +4.58% | +12.42% | |
| Oncocyte to Announce Third Quarter 2023 Financial Results | Press release | — | +8.09% |
Keep exploring
More OCX: analyst actions → · SEC filings → · OCX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| G1 Therapeutics, Inc. (GTHX) | 142 | +0.21% | 66% |
| InflaRx N.V. (IFRX) | 142 | 0.00% | 48% |
| ImmunoGen, Inc. (IMGN) | 140 | +0.07% | 56% |
| MEDIFIRST SOLUTIONS (MFST) | 140 | 0.00% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.